Annuncio • Mar 04
Bellicum Pharmaceuticals Files Form 15 Bellicum Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share. Annuncio • Feb 22
The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM). The University of Texas M. D. Anderson Cancer Center agreed to acquire substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) for $8.1 million on November 21, 2023. Pursuant to the asset purchase agreement, MDACC will pay to Bellicum an amount equal to $8.1 million in cash and will assume certain related liabilities. The transaction is subject to receive approval from Bellicum’s stockholders and certain other customary closing conditions. The asset purchase agreement has been approved by the board of directors of Bellicum and The Board of Regents of the University of Texas System (the “UT Board of Regents”), the governing body for the University of Texas System. Matthew Browne, Rowook Park and Matthew Silverman of Cooley LLP acted as legal advisors to Bellicum Pharmaceuticals. Roger J. Griesmeyer of Katten Muchin Rosenman LLP acted as legal advisors to The University of Texas M.D. Anderson Cancer Center.The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) on February 21, 2024. As of January 29, 2024, the transaction has been approved by the shareholders of Bellicum Pharmaceuticals. Annuncio • Jul 08
Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals Nasdaq announced on July 6, 2023 that it will delist the common stock of Bellicum Pharmaceuticals, Inc. The company’s securities were suspended on June 2, 2023, and have not traded on Nasdaq since that time. Annuncio • Jun 03
Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index Bellicum Pharmaceuticals, Inc. has been dropped from NASDAQ Composite Index. Annuncio • May 31
Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1) As previously disclosed by Bellicum Pharmaceuticals, Inc., pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM". Major Estimate Revision • May 21
Consensus EPS estimates fall by 39% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.49 to -US$0.68 per share. Revenue forecast of US$8.0k unchanged since last update. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$5.00 unchanged from last update. Share price rose 5.8% to US$0.79 over the past week. Annuncio • Feb 17
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium Bellicum Pharmaceuticals, Inc. will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients. These initial data from 2 cohorts consisted of 8 patients who received lympodepleting chemotherapy (fludarabine + cyclophosphamide) followed by a single dose of 5x106 BPX-601 cells/kg and single (n=3) or weekly (n=5) doses of 0.4 mg/kg rimiducid beginning 7 days following the cell infusion. GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40. The trial continues to enroll patients. The next cohorts in the Phase 1 trial will explore higher doses of rimiducid, which in non-clinical studies have been shown to increase GoCAR-T persistence, enhance pro-inflammatory cytokine production, and improve anti-tumor efficacy. Annuncio • Dec 12
Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid Bellicum Pharmaceuticals, Inc. announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial. The poster titled “Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)” will also be available on Bellicum’s website. The UNC Lineberger research team reported the clinical and pharmacodynamic courses of ICANS for four patients treated with rimiducid in an ongoing cell dose expansion cohort of a Phase I/II trial of iC9 CAR.19 cells to treat B-lymphoblastic leukemia (B-ALL). According to the poster, rimiducid administration to these patients experiencing corticosteroid-unresponsive grade 3-4 ICANS was associated with abrupt reduction of circulating iC9 CAR.19 cells and lower ICANS grade within 24 hours. The UNC Lineberger research team concluded that iC9 holds promise as a tool to potentially abrogate the most severe CAR T-cell toxicities. The UNC Lineberger team is exploring lower doses of rimiducid to determine if—by preserving a higher percentage of CAR-T cells—toxicity may be mitigated without diminishing the therapeutic benefit. Price Target Changed • Nov 16
Price target decreased to US$5.00 Down from US$17.33, the current price target is provided by 1 analyst. New target price is 367% above last closing price of US$1.07. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$1.68 next year compared to a net loss per share of US$0.84 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • May 02
Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022 Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022, at 13:00 Pacific Standard Time. Agenda: To elect one Class II director named herein to hold office until the 2025 Annual Meeting of Stockholders; to approve an amendment to the Company’s 2019 Equity Incentive Plan to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 Plan by 2,250,000 shares; to ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors to serve as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement; and to consider other matters if any. Price Target Changed • Apr 27
Price target decreased to US$5.00 Down from US$17.33, the current price target is provided by 1 analyst. New target price is 202% above last closing price of US$1.66. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$2.82 next year compared to a net loss per share of US$0.84 last year. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improved over the past week After last week's 18% share price gain to US$1.80, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 8x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improved over the past week After last week's 34% share price gain to US$1.90, the stock trades at a trailing P/E ratio of 2.4x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years. Annuncio • Feb 16
Bellicum Pharmaceuticals, Inc. Announces Board Changes On February 14, 2022, James F. Brown notified Bellicum Pharmaceuticals, Inc. (the “Company”) of his resignation from his position as a member of the Company’s Board of Directors (the “Board”), including each committee of the Board on which he is a member, to be effective as of immediately prior to the Company’s 2022 annual meeting of stockholders. Effective as of Mr. Brown’s resignation, Jon P. Stonehouse will serve as interim Chairman of the Board. Annuncio • Dec 15
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements Bellicum Pharmaceuticals, Inc. announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the company’s recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company. Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$1.72, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 27x in the Biotechs industry in the US. Total loss to shareholders of 96% over the past three years. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$2.26, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment deteriorated over the past week After last week's 15% share price decline to US$3.00, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 25x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 18% share price gain to US$3.32, the stock trades at a trailing P/E ratio of 6.2x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years. Annuncio • May 19
Bellicum Pharmaceuticals, Inc. Provides an Operational Update Bellicum Pharmaceuticals, Inc. provided an operational update. BPX-601 GoCAR-T® •Patient enrollment is ongoing in the Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. •Bellicum plans to present a Phase 1 data update on BPX-601 and rimiducid in patients with metastatic castration-resistant prostate cancer in the first quarter of 2022. BPX-603 GoCAR-T•Bellicum is conducting its Phase 1/2 clinical trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2 (HER2), including breast, endometrial, ovarian, gastric, and colorectal cancers. BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates Bellicum’s iMC activation and CaspaCIDe® safety switch technologies. The company expects to present initial Phase 1 data from this trial in the fourth quarter of 2021. CaspaCIDe
•As announced in February, the first reported use of the CaspaCIDe safety switch to mitigate CAR-T cell toxicity was published as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. The report described a case from an investigator-sponsored trial at the University of North Carolina Lineberger Comprehensive Cancer Center of autologous CAR-T cells expressing CD19 and CaspaCIDe. In this patient, grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) refractory to standard therapies was treated with rimiducid to activate CaspaCIDe. Within 12 hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days. Reported Earnings • Apr 01
Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019) Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Annuncio • Mar 31
Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020 Bellicum Pharmaceuticals, Inc. reported impairment for the fourth quarter ended December 31, 2020. For the quarter, Impairment of property and equipment was $1,265,000. Annuncio • Mar 06
Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity Bellicum Pharmaceuticals, Inc. announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch. The letter to the editor titled “Utility of Safety Switch to Abrogate CD 19 CAR T Cell-Associated Neurotoxicity” appeared as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. Link to article. The publication detailed a case report from an investigator-sponsored trial (IST) at the University of North Carolina Lineberger Comprehensive Cancer Center, where a Phase 1/2 trial is ongoing to test the safety and efficacy of autologous T lymphocytes genetically modified to express a CD19 chimeric antigen receptor (CAR) and iC9. A patient in the dose expansion cohort of this trial experienced a high grade neurologic adverse event with persistence of grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) for 72 hours despite standard care, and rimiducid was subsequently given per protocol to activate iC9. Within twelve hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days. This publication marked the first reported clinical use of the iC9 safety switch to mitigate a severe CAR-T-mediated adverse event refractory to standard of care treatment. Is New 90 Day High Low • Jan 30
New 90-day high: US$4.65 The company is up 25% from its price of US$3.71 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 25% over the same period. Price Target Changed • Jan 30
Price target lowered to US$4.50 Down from US$17.33, the current price target is an average from 2 analysts. The new target price is close to the current share price of US$4.65. As of last close, the stock is down 62% over the past year. Annuncio • Jan 29
Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial Bellicum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with the FDA over the past two months to respond to the clinical hold and has been informed by FDA that the company has satisfactorily addressed all clinical hold issues. Bellicum may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment. About BPX-601: BPX-601, the company’s first GoCAR-T product candidate, incorporates iMC, Bellicum’s inducible co-activation domain. iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence, production of immunomodulatory cytokines and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA). Annuncio • Jan 28
Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index Annuncio • Jan 12
Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021 On January 5, 2021, David Strauss notified Bellicum Pharmaceuticals, Inc. of his resignation from his position as the Company’s Senior Director, Corporate Controller, and as the Company’s principal accounting officer, to be effective January 22, 2021. Annuncio • Dec 12
Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603 Bellicum Pharmaceuticals, Inc. announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T® product candidate that incorporates the company’s iMC activation and CaspaCIDe® safety switch technologies. This Phase 1/2, open-label, multicenter, non-randomized study will investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid. The trial will enroll patients with previously treated, locally advanced or metastatic solid tumors with HER2 amplification or overexpression. The initial dose escalation phase of the trial is designed to evaluate safety and identify the Phase 2 dose of BPX-603 administered with rimiducid at a fixed dose of 0.4 mg/kg per infusion. The Phase 2 portion of the trial will assess the safety, pharmacodynamics, and clinical activity of BPX-603 in various HER2+ solid tumors. Tumor types that may be studied include gastric, breast, ovarian, endometrial, and colorectal. Annuncio • Dec 10
Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial Bellicum Pharmaceuticals, Inc. announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid. The company plans to work diligently with the FDA to address the agency’s questions and fulfill the requirements for resuming the trial. The clinical hold does not affect the company’s plans to initiate enrollment in the Phase 1/2 clinical trial of BPX-603, a dual switch GoCAR-T®, in patients with HER2+ solid tumors by the end of the year. Annuncio • Oct 30
Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020 Bellicum Pharmaceuticals, Inc. staff will be reduced by 79%, from 68 to 14 full-time employees by the end of 2020. Annuncio • Sep 29
Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019 Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2018 results at 9:01 PM, GMT Standard Time on Mar 12, 2019 Annuncio • Jul 31
The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM). The University of Texas MD Anderson Cancer Center entered into an asset purchase agreement to acquire certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) for $15 million on January 17, 2020. The purchase price of $15 million is payable in cash upon closing, less $1.5 million to be held in escrow for up to 18 months after the closing of the transaction. Under the transaction, The University of Texas MD Anderson Cancer Center will acquire approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space. Approximately 35 employees currently employed at the facility will be employed by MD Anderson. The transaction is subject to approval of the Board of Regents of the University of Texas System, the entry into a master services agreement between Bellicum and The University of Texas MD Anderson Cancer Center, completion of an on-site inspection of the facility by certain regulatory entities, Bellicum obtaining consent from the landlord of the facility, and the satisfaction of customary terms and conditions, including adjustment to the purchase price. The transaction is expected to close on or before February 21, 2020. As of March 12, 2020, the closing of the transaction is expected to occur on or before March 31, 2020. Andrew L. Strong of Pillsbury Winthrop Shaw Pittman LLP acted as legal advisor to Bellicum and Roger Griesmeyer of Hunton Andrews Kurth LLP acted as legal advisor to The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) on April 15, 2020. Annuncio • Jul 03
Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index